Literature DB >> 1357663

Prion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindred.

G Giaccone1, L Verga, O Bugiani, B Frangione, D Serban, S B Prusiner, M R Farlow, B Ghetti, F Tagliavini.   

Abstract

Gerstmann-Sträussler-Scheinker disease (GSS) is a familial neurological disorder pathologically characterized by amyloid deposition in the cerebrum and cerebellum. In GSS, the amyloid is immunoreactive to antisera raised against the prion protein (PrP) 27-30, a proteinase K-resistant peptide of 27-30 kDa that is derived by limited proteolysis from an abnormal isoform of a neuronal sialoglycoprotein of 33-35 kDa designated PrPSc. Polyclonal antibodies raised against synthetic peptides homologous to residues 15-40 (P2), 90-102 (P1), and 220-232 (P3) of the amino acid sequence deduced from hamster PrP cDNA were used to investigate immunohistochemically the distribution of PrP and PrP fragments in the brains of two patients from the Indiana kindred of GSS. Two types of anti-PrP-immunoreactive deposits were found: (i) amyloid deposits, which were exclusively labeled by anti-P1 antiserum to residues 90-102 of PrP, and (ii) preamyloid deposits, which were labeled by all anti-PrP antisera but did not exhibit the tinctorial and optical properties of amyloid. The latter appeared as diffuse immunostaining of the neuropil that targeted to areas in which amyloid deposits were most abundant. They were partially resistant to proteinase K digestion and consisted ultrastructurally of amorphous, flaky, electron-dense material. These findings substantiate our previous observation that the major amyloid component in the GSS Indiana kindred is an internal fragment of PrP and indicate that full-length abnormal isoforms of PrP and/or large PrP fragments accumulate in brain regions most affected by amyloid deposition. These findings support the view that in the GSS Indiana kindred a stepwise degradation of PrP occurs in situ in the process of amyloid fibril formation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357663      PMCID: PMC50124          DOI: 10.1073/pnas.89.19.9349

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Protein A-gold immunoelectron microscopic study of amyloid fibrils, granular deposits, and fibrillar luminal aggregates in renal amyloidosis.

Authors:  G C Yang; G R Gallo
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

2.  N-terminal sequence of prion protein is also integrated into kuru plaques in patients with Gerstmann-Sträussler syndrome.

Authors:  T Kitamoto; T Muramoto; C Hilbich; K Beyreuther; J Tateishi
Journal:  Brain Res       Date:  1991-04-05       Impact factor: 3.252

3.  Scrapie prion protein contains a phosphatidylinositol glycolipid.

Authors:  N Stahl; D R Borchelt; K Hsiao; S B Prusiner
Journal:  Cell       Date:  1987-10-23       Impact factor: 41.582

4.  Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization.

Authors:  M M Picken; B Frangione; B Barlogie; M Luna; G Gallo
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

5.  Alzheimer patients: preamyloid deposits are more widely distributed than senile plaques throughout the central nervous system.

Authors:  O Bugiani; G Giaccone; B Frangione; B Ghetti; F Tagliavini
Journal:  Neurosci Lett       Date:  1989-09-11       Impact factor: 3.046

Review 6.  [Mutation of codon 117 of the prion gene in Gerstmann-Sträussler-Scheinker disease].

Authors:  C Tranchant; K Doh-Ura; G Steinmetz; Y Chevalier; T Kitamoto; J Tateishi; J M Warter
Journal:  Rev Neurol (Paris)       Date:  1991       Impact factor: 2.607

7.  Neurofibrillary tangles of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease share antigenic determinants with those of Alzheimer disease.

Authors:  G Giaccone; F Tagliavini; L Verga; B Frangione; M R Farlow; O Bugiani; B Ghetti
Journal:  Brain Res       Date:  1990-10-22       Impact factor: 3.252

8.  Immunochemical, molecular genetic, and transmission studies on a case of Gerstmann-Sträussler-Scheinker syndrome.

Authors:  J Tateishi; T Kitamoto; K Doh-ura; Y Sakaki; G Steinmetz; C Tranchant; J M Warter; N Heldt
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

9.  Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene.

Authors:  S R Dlouhy; K Hsiao; M R Farlow; T Foroud; P M Conneally; P Johnson; S B Prusiner; M E Hodes; B Ghetti
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

10.  Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication.

Authors:  S B Prusiner; M Scott; D Foster; K M Pan; D Groth; C Mirenda; M Torchia; S L Yang; D Serban; G A Carlson
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

View more
  25 in total

Review 1.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

2.  Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease.

Authors:  Alejandro M Sevillano; Patricia Aguilar-Calvo; Timothy D Kurt; Jessica A Lawrence; Katrin Soldau; Thu H Nam; Taylor Schumann; Donald P Pizzo; Sofie Nyström; Biswa Choudhury; Hermann Altmeppen; Jeffrey D Esko; Markus Glatzel; K Peter R Nilsson; Christina J Sigurdson
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia.

Authors:  J L Holton; J Ghiso; T Lashley; A Rostagno; C J Guerin; G Gibb; H Houlden; H Ayling; L Martinian; B H Anderton; N W Wood; R Vidal; G Plant; B Frangione; T Revesz
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity.

Authors:  Xing Wei; Yvonne Roettger; Bailin Tan; Yongzheng He; Richard Dodel; Harald Hampel; Gang Wei; Jillian Haney; Huiying Gu; Brian H Johnstone; Junyi Liu; Martin R Farlow; Yansheng Du
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 5.  Prions, beta-sheets and transmissible dementias: is there still something missing?

Authors:  P P Liberski
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

6.  A kinetic model for amyloid formation in the prion diseases: importance of seeding.

Authors:  J H Come; P E Fraser; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

7.  Diffuse senile plaques: amorphous or fibrous?

Authors:  O Bugiani; F Tagliavini; G Giaccone; L Verga; K el-Hachimi; J F Foncin; B Frangione
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

8.  Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro.

Authors:  F Tagliavini; F Prelli; L Verga; G Giaccone; R Sarma; P Gorevic; B Ghetti; F Passerini; E Ghibaudi; G Forloni
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

9.  Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring.

Authors:  Bruce Chesebro; Brent Race; Kimberly Meade-White; Rachel Lacasse; Richard Race; Mikael Klingeborn; James Striebel; David Dorward; Gillian McGovern; Martin Jeffrey
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

10.  Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy.

Authors:  H F Baker; R M Ridley; L W Duchen; T J Crow; C J Bruton
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.